358 research outputs found

    Can biogas digesters help to reduce deforestation in Africa?

    Get PDF
    Acknowledgements The authors are grateful for financial support for this work in part from the UK Department for International Development (DFID) New and Emerging Technologies Research Call, and in part from the EU under the REDD-ALERT (Reducing Emissions from Deforestation and Degradation from Alternative Land Uses in Rainforests of the Tropics) project, Grant agreement number 226310. The authors thank Dr Hoang Viet Anh, Dr Suyanto and Mr. Gamma Galudra for their input on the manuscript.Peer reviewedPostprin

    Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review

    Get PDF
    The COVID-19 pandemic, caused by SARS-CoV-2, continues to impact global health regarding both morbidity and mortality. Although SARS-CoV-2 primarily causes acute respiratory distress syndrome (ARDS), the virus interacts with and influences other organs and tissues, including blood vessel endothelium, heart, gastrointestinal tract, and brain. We are learning much about the pathophysiology of SARS-CoV-2 infection; however, we are just beginning to study and understand the long-term and chronic health consequences. Since the pandemic’s beginning in late 2019, older adults, those with pre-existing illnesses, or both, have an increased risk of contracting COVID-19 and developing severe COVID-19. Furthermore, older adults are also more likely to develop the neurodegenerative disorder Parkinson’s disease (PD), with advanced age as the most significant risk factor. Thus, does SARS-CoV-2 potentially influence, promote, or accelerate the development of PD in older adults? Our initial focus was aimed at understanding SARS-CoV-2 pathophysiology and the connection to neurodegenerative disorders. We then completed a literature review to assess the relationship between PD and COVID-19. We described potential molecular and cellular pathways that indicate dopaminergic neurons are susceptible, both directly and indirectly, to SARS-CoV-2 infection. We concluded that under certain pathological circumstances, in vulnerable persons-with-Parkinson’s disease (PwP), SARS-CoV-2 acts as a neurodegenerative enhancer to potentially support the development or progression of PD and its related motor and non-motor symptoms

    Spectroscopic Target Selection in the Sloan Digital Sky Survey: The Quasar Sample

    Get PDF
    We describe the algorithm for selecting quasar candidates for optical spectroscopy in the Sloan Digital Sky Survey. Quasar candidates are selected via their non-stellar colors in "ugriz" broad-band photometry, and by matching unresolved sources to the FIRST radio catalogs. The automated algorithm is sensitive to quasars at all redshifts lower than z=5.8. Extended sources are also targeted as low-redshift quasar candidates in order to investigate the evolution of Active Galactic Nuclei (AGN) at the faint end of the luminosity function. Nearly 95% of previously known quasars are recovered (based on 1540 quasars in 446 square degrees). The overall completeness, estimated from simulated quasars, is expected to be over 90%, whereas the overall efficiency (quasars:quasar candidates) is better than 65%. The selection algorithm targets ultraviolet excess quasars to i^*=19.1 and higher-redshift (z>3) quasars to i^*=20.2, yielding approximately 18 candidates per square degree. In addition to selecting ``normal'' quasars, the design of the algorithm makes it sensitive to atypical AGN such as Broad Absorption Line quasars and heavily reddened quasars.Comment: 62 pages, 15 figures (8 color), 8 tables. Accepted by AJ. For a version with higher quality color figures, see http://archive.stsci.edu/sdss/quasartarget/RichardsGT_qsotarget.preprint.p

    An Erupting Classical Nova in a Globular Cluster of M87

    Full text link
    Only one certain classical nova eruption has ever been detected inside a globular cluster - nova 1860 A.D. (T Sco) in M80. During a survey of M87 we have detected an erupting star coincident (to within 0.08 pixels) with a globular cluster of that giant elliptical galaxy. We are able to discount variables in the foreground or background of M87. The light curve and color of the erupting star match those expected for a nova at the distance of M87. The chance superposition of an M87 field nova on the globular cluster is very unlikely but cannot be completely ruled out.Our detection hints at a globular cluster nova frequency f.004f \sim .004 novae/cluster/year, much higher than previous observations have suggested

    Physical and dynamical properties of the main belt triple asteroid (87) Sylvia

    Full text link
    We present the analysis of high angular resolution observations of the triple Asteroid (87) Sylvia collected with three 8-10 m class telescopes (Keck, VLT, Gemini North) and the Hubble Space Telescope. The moons' mutual orbits were derived individually using a purely Keplerian model. We computed the position of Romulus, the outer moon of the system, at the epoch of a recent stellar occultation which was successfully observed at less than 15 km from our predicted position, within the uncertainty of our model. The occultation data revealed that the Moon, with a surface-area equivalent diameter Ds=23.1±\pm0.7km, is strongly elongated (axes ratio of 2.7±\pm0.32.7±\pm0.3), significantly more than single asteroids of similar size in the main-belt. We concluded that its shape is probably affected by the tides from the primary. A new shape model of the primary was calculated combining adaptive-optics observations with this occultation and 40 archived light-curves recorded since 1978. The difference between the J2=0.024-0.009+0.016 derived from the 3-D shape model assuming an homogeneous distribution of mass for the volume equivalent diameter Dv=273±\pm10km primary and the null J2 implied by the Keplerian orbits suggests a non-homogeneous mass distribution in the asteroid's interior

    Photometric Calibration of the Swift Ultraviolet/Optical Telescope

    Full text link
    We present the photometric calibration of the Swift UltraViolet/Optical Telescope (UVOT) which includes: optimum photometric and background apertures, effective area curves, colour transformations, conversion factors for count rates to flux, and the photometric zero points (which are accurate to better than 4 per cent) for each of the seven UVOT broadband filters. The calibration was performed with observations of standard stars and standard star fields that represent a wide range of spectral star types. The calibration results include the position dependent uniformity, and instrument response over the 1600-8000A operational range. Because the UVOT is a photon counting instrument, we also discuss the effect of coincidence loss on the calibration results. We provide practical guidelines for using the calibration in UVOT data analysis. The results presented here supersede previous calibration results.Comment: Minor improvements after referees report. Accepted for publication in MNRA

    Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. The VANISH Randomized Clinical Trial

    Get PDF
    IMPORTANCE: Norepinephrine is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative. OBJECTIVE: To compare the effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: A factorial (2×2), double-blind, randomized clinical trial conducted in 18 general adult intensive care units in the United Kingdom between February 2013 and May 2015, enrolling adult patients who had septic shock requiring vasopressors despite fluid resuscitation within a maximum of 6 hours after the onset of shock. INTERVENTIONS: Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepinephrine and placebo (n = 103). MAIN OUTCOMES AND MEASURES: The primary outcome was kidney failure-free days during the 28-day period after randomization, measured as (1) the proportion of patients who never developed kidney failure and (2) median number of days alive and free of kidney failure for patients who did not survive, who experienced kidney failure, or both. Rates of renal replacement therapy, mortality, and serious adverse events were secondary outcomes. RESULTS: A total of 409 patients (median age, 66 years; men, 58.2%) were included in the study, with a median time to study drug administration of 3.5 hours after diagnosis of shock. The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%) in the vasopressin group and 93 of 157 patients (59.2%) in the norepinephrine group (difference, -2.3% [95% CI, -13.0% to 8.5%]). The median number of kidney failure-free days for patients who did not survive, who experienced kidney failure, or both was 9 days (interquartile range [IQR], 1 to -24) in the vasopressin group and 13 days (IQR, 1 to -25) in the norepinephrine group (difference, -4 days [95% CI, -11 to 5]). There was less use of renal replacement therapy in the vasopressin group than in the norepinephrine group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.9% [95% CI, -19.3% to -0.6%]). There was no significant difference in mortality rates between groups. In total, 22 of 205 patients (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients (8.3%) in the norepinephrine group (difference, 2.5% [95% CI, -3.3% to 8.2%]). CONCLUSIONS AND RELEVANCE: Among adults with septic shock, the early use of vasopressin compared with norepinephrine did not improve the number of kidney failure-free days. Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin, and larger trials may be warranted to assess this further. TRIAL REGISTRATION: clinicaltrials.gov Identifier: ISRCTN 20769191
    corecore